These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33751604)

  • 1. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.
    Fouad Y; Lazarus JV; Negro F; Peck-Radosavljevic M; Sarin SK; Ferenci P; Esmat G; Ghazinian H; Nakajima A; Silva M; Lee S; Colombo M
    Aliment Pharmacol Ther; 2021 May; 53(10):1080-1089. PubMed ID: 33751604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatitis C in a psychiatric setting: A forgotten reservoir?].
    Rolland B; Bailly F; Cutarella C; Drevon O; Carrieri P; Darque A; Hallouche N; Maptue N; Pol S; Llorca PM; Lang JP
    Encephale; 2021 Apr; 47(2):181-184. PubMed ID: 32473777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.
    Wirth TC; Manns MP
    Ann Oncol; 2016 Aug; 27(8):1467-74. PubMed ID: 27226385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide prevalence, genotype distribution and management of hepatitis C.
    Guntipalli P; Pakala R; Kumari Gara S; Ahmed F; Bhatnagar A; Endaya Coronel MK; Razzack AA; Solimando AG; Thompson A; Andrews K; Enebong Nya G; Ahmad S; Ranaldo R; Cozzolongo R; Shahini E
    Acta Gastroenterol Belg; 2021; 84(4):637-656. PubMed ID: 34965046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long.
    Brouard C; Pillonel J; Boussac M; de Lédinghen V; Rachas A; Silvain C; Lydié N; Chevaliez S; Pioche C; Durand J; Lot F; Delarocque-Astagneau E
    BMC Infect Dis; 2020 Oct; 20(1):759. PubMed ID: 33059617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
    Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
    Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy for the Elimination of Hepatitis C in Cantabria.
    Crespo J; Tejerina Puente A; Cuadrado A; Llerena S; Cabezas J;
    Rev Esp Enferm Dig; 2020 Jul; 112(7):565-570. PubMed ID: 32543873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
    Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
    N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.
    Muzica CM; Stanciu C; Huiban L; Singeap AM; Sfarti C; Zenovia S; Cojocariu C; Trifan A
    World J Gastroenterol; 2020 Nov; 26(43):6770-6781. PubMed ID: 33268960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In-hospital process for viral hepatitis C screening and management in China (Draft)].
    ; ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):319-325. PubMed ID: 33979957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H; Dore GJ; Ward JW
    J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
    Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
    He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ
    Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.